BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32197474)

  • 1. CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA.
    Binda CS; Klaver B; Berkhout B; Das AT
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32197474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.
    Wang G; Zhao N; Berkhout B; Das AT
    Cell Rep; 2016 Dec; 17(11):2819-2826. PubMed ID: 27974196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.
    Darcis G; Binda CS; Klaver B; Herrera-Carrillo E; Berkhout B; Das AT
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30871200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed
    Ophinni Y; Miki S; Hayashi Y; Kameoka M
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.
    Wang G; Zhao N; Berkhout B; Das AT
    Mol Ther; 2016 Mar; 24(3):522-6. PubMed ID: 26796669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.
    Smith LM; Ladner JT; Hodara VL; Parodi LM; Harris RA; Callery JE; Lai Z; Zou Y; Raveedran M; Rogers J; Giavedoni LD
    J Virol; 2021 Nov; 95(23):e0088221. PubMed ID: 34549979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
    Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
    EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
    Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
    Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.
    Liu Y; Jeeninga RE; Klaver B; Berkhout B; Das AT
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
    Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
    J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of infectious HIV DNA by CRISPR-Cas9.
    Das AT; Binda CS; Berkhout B
    Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9.
    Yoder KE; Bundschuh R
    Sci Rep; 2016 Jul; 6():29530. PubMed ID: 27404981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
    Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
    Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients.
    Sullivan NT; Dampier W; Chung CH; Allen AG; Atkins A; Pirrone V; Homan G; Passic S; Williams J; Zhong W; Kercher K; Desimone M; Li L; C Antell G; Mell JC; Ehrlich GD; Szep Z; Jacobson JM; Nonnemacher MR; Wigdahl B
    Sci Rep; 2019 Nov; 9(1):17088. PubMed ID: 31745112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
    Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
    Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas.
    Mefferd AL; Bogerd HP; Irwan ID; Cullen BR
    Virology; 2018 Jul; 520():116-126. PubMed ID: 29857168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA.
    Liu Y; Binda CS; Berkhout B; Das AT
    J Virol; 2023 Dec; 97(12):e0133423. PubMed ID: 37982648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.